Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma

Abstract We performed the first in-depth, comparative and prospective biomonitoring of Multiple Myeloma (MM) patients (N = 39) receiving ciltacabtagene autoleucel (cilta-cel) or idecabtagene vicleucel (ide-cel) chimeric antigen receptor T cells (CAR T) in the real-world setting. In cilta-cel patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Djordje Atanackovic, Tim Luetkens, Dina Schneider, Peirong Hu, Xu Wang, Amol C. Shetty, Luke Tallon, Imari Patel, Rohan Singh, Etse Gebru, Rediet Mulatu, Destiny Omili, Daniel Yamoah, Xiaoxuan Fan, Aerielle Matsangos, Patricia Lesho, Kenneth A. Dietze, Ariel A. Fromowitz, Kim G. Hankey, Saurabh Dahiya, Jean A. Yared, Nancy M. Hardy, Rima Koka, Michael E. Kallen, Ashraf Badros, Aaron P. Rapoport, Mehmet H. Kocoglu
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-60980-2
Tags: Add Tag
No Tags, Be the first to tag this record!